← All stocks

PTC THERAPEUTICS, INC.

PTCT Mostly scheduled
CIK 0001070081 #1239 in the set updated 17 Sep 2026
Bought (120 mo)
$2.86M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$222.08M
$24.98M on a plan · $191.69M straight out of an exercise
Sold at will
$5.41M
150 of 767 sales
Net
−$219.22M
−$2.55M against sales at will

By person

27 insiders · 785 transactions
26.9×

Matthew B. Klein holds 26.9 times base salary in stock. $25.85M of shares against $958.50K in salary for 2025.

Salary from the company's own proxy. The shares are what Matthew B. Klein last reported holding, valued at $67.34, the price Common Stock was last bought or sold at on the open market here, on 10 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Peltz Stuart Walter
CHIEF EXECUTIVE OFFICER
$73.94M (115) scheduled
−$73.94M
221,865
$14.94M
+698.3%
Almstead Neil Gregory
CHIEF TECHNICAL OPS OFFICER
$42.26M (139) scheduled
−$42.26M
63,036
$4.24M
+437.6%
Boulding Mark Elliott
EXEC. VP AND CLO
$35.32M (163) scheduled
−$35.32M
105,272
$7.09M
+412.9%
Pauwels Eric
CHIEF BUSINESS OFFICER
$12.63M (71) scheduled
−$12.63M
73,411
$4.94M
+195.0%
Utter Christine Marie
SVP, CHIEF ACCOUNTING OFFICER
$10.93M (80) scheduled
−$10.93M
70,199
$4.73M
+466.7%
Klein Matthew B.
CHIEF EXECUTIVE OFFICER
$7.92M (38) scheduled
−$7.92M
383,868
$25.85M
+11,091%
Jacobson Allan Steven
Director
$7.08M (23) scheduled
−$7.08M
21,451
$1.44M
+213.2%
Reeve Emma
Director
$6.12M (29) scheduled
−$6.12M
10,666
$718.25K
Souza Marcio
Chief Operating Officer
$5.48M (15) scheduled
−$5.48M
56,841
$3.83M
+34.2%
SOUTHWELL DAVID P
Director
$3.25M (11) scheduled
−$3.25M
20,850
$1.40M
Hill Emily Luisa
CHIEF FINANCIAL OFFICER
$2.86M (24) scheduled
−$2.86M
38,925
$2.62M
+411.8%
SCHMERTZLER MICHAEL
Director
$2.32M (2)
$5.05M (14) scheduled
−$2.73M
2,816,454
$189.66M
+4.9%
ZELDIS JEROME B
Director
$2.00M (6) scheduled
−$2.00M
22,500
$1.52M
Okey Stephanie
Director
$1.96M (7) scheduled
−$1.96M
8,000
$538.72K
+242.9%
Smith Mary L.
Director
$1.43M (2) scheduled
−$1.43M
21,813
$1.47M
Golden Lee Scott
EVP & CHIEF MEDICAL OFFICER
$1.38M (15) scheduled
−$1.38M
79,115
$5.33M
+91.6%
STEELE GLENN JR MD PHD
Director
$916.20K (1) scheduled
−$916.20K
22,500
$1.52M
Gravier Pierre
CHIEF FINANCIAL OFFICER
$198.74K (1)
$971.51K (7) scheduled
−$772.78K
83,986
$5.66M
+5,769%
Young Alethia
Director
$464.97K (2) scheduled
−$464.97K
21,067
$1.42M
Svoronos Dawn
Director
$337.23K (1)
$101.43K (5)
+$235.80K
29,017
$1.95M
Sollie-Zetlmayer Hege Elisabeth
Director
52,526
$3.54M
+12.9%
Kovacs Shane William Charles
Chief Financial Officer
37,850
$2.55M
+327.7%
Rothera Mark
Chief Commercial Officer
33,739
$2.27M
+393.8%
Bell William F. Jr.
Director
10,333
$695.82K
Chutter Jessica Caroline
Director
7,333
$493.80K
Ong Tuyen
Chief Medical Officer
6,000
$404.04K
Complete Pharma Holdings II, LLC entity
10% owner
0
$0.00
−100.0%

No percentages here. This company's share count has moved by a factor of 10.1 over the window, from 8,294,933 to 83,460,802 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
SCHMERTZLER MICHAEL
16 Dec 2025
Director
Exercised, kept
24,000
$30.86
$740.64K
Showing 250 of 785 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 457
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 148
Sales straight out of an exercise 469
Sales at will 150
Transactions with no price 0
Shares from compensation/vesting 11,762,489
Sales filed before the plan box existed 145
History held since 26 Sep 2016